Abstract: The disclosure provides methods of treating solid tumors with a combination of tucatinib, or salt or solvent thereof, and an anti-PD-1 antibody, or an antigen-binding fragment thereof. The disclosure also provides methods of treating solid tumors with a combination of tucatinib, or salt or solvent thereof, and an anti-PD-L1 antibody, or an antigen-binding fragment thereof.

Abstract: Wheelbarrow accessories are presented including: a base for mechanically coupling with a pair of wheelbarrow arms; and an extendable arm assembly mechanically coupled with the base where the extendable arm assembly is vertically adjustable, the extendable arm assembly including; an outer arm pivotally engaged with the base; an inner arm slidingly engaged with the outer arm along an inner surface of the outer arm, where the inner arm is adjustable to a number of extendable arm lengths; a pad base coupled with the inner arm along a distal end of the inner arm; and a pad coupled with the pad base.

Abstract: In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.

Abstract: This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.

Abstract: Some embodiments provide a network forwarding IC with packet processing pipelines, at least one of which includes a parser, a set of match-action stages, and a deparser. The parser is configured to receive a packet and generate a PHV including a first number of data containers storing data for the packet. A first match-action stage is configured to receive the PHV from the parser and expand the PHV to a second, larger number of data containers storing data for the packet. Each of a set of intermediate match-action stage is configured to receive the expanded PHV from a previous stage and provide the expanded PHV to a subsequent stage. A final match-action stage is configured to receive the expanded PHV and reduce the PHV to the first number of data containers. The deparser is configured to receive the reduced PHV from the final match-action stage and reconstruct the packet.

Abstract: The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.

Abstract: Some embodiments provide a network forwarding IC with packet processing pipelines, at least one of which includes a parser, a set of match-action stages, and a deparser. The parser is configured to receive a packet and generate a PHV including a first number of data containers storing data for the packet. A first match-action stage is configured to receive the PHV from the parser and expand the PHV to a second, larger number of data containers storing data for the packet. Each of a set of intermediate match-action stage is configured to receive the expanded PHV from a previous stage and provide the expanded PHV to a subsequent stage. A final match-action stage is configured to receive the expanded PHV and reduce the PHV to the first number of data containers. The deparser is configured to receive the reduced PHV from the final match-action stage and reconstruct the packet.

Abstract: In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.

Abstract: The invention provides methods of treating cancer, such as cancers with a HER2 mutation, with tucatinib, or salt or solvate thereof. The invention also provides compositions and kits comprising tucatinib for use in treating cancer, such as cancers with a HER2 mutation.

Abstract: Isolated antibodies or antigen-binding portions that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody or antigen-binding portion thereof has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT.

Abstract: An interfragmentary guide and plate system is described.

Abstract: This disclosure provides anti-apolipoprotein L1 (APOL1) antibodies, including anti-APOL1 antibodies that distinguish the GO and G1 forms from the G2 form of APOL1, distinguish APOL1 found on podocytes from that found on HDL particles in serum, and distinguish APOL1 from apolipoproteins L2, L3, L4 and L6 (APOL2, APOL3, APOL4 and APOL6), and methods of using the same.

Abstract: Isolated antibodies that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT. In some embodiments, the antibodies are afucosylated.

Abstract: The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.

Abstract: A plating system includes a bone plate including an aperture. A locking member is receivable in the aperture to attach the bone plate to a joint. The plating system includes a guide including a body having a first end portion, a second end portion, an attachment portion attached to the bone plate, and a rotating portion including a sleeve to receive a drill or a guide wire. The first end portion of the body is rotationally connected to the attachment portion to pivot the body about a first axis to move the sleeve, and the rotating portion is rotationally connected to the second end portion of the body of the guide to pivot the rotating portion about a second axis to move the sleeve. The rotating portion translates along the second axis to move the sleeve, and the sleeve defines one of a plurality of trajectories.

Abstract: Described herein are methods and compositions for treating, reducing, or ameliorating cancer in a subject, comprising administering compositions comprising mucin and/or inulin. In some aspects, described herein is a method of enhancing anti-cancer immunity comprising: (a) administering to a subject a composition comprising mucin, wherein the subject has been identified as having a gut microbiome comprising one more microbial taxa that are members of a Clostridium cluster XIVa or an Actinobacteria phylum; and (b) altering the gut microbiome in the subject, wherein administration of the composition causes an enhanced anti-cancer immunity in the subject.

Abstract: Systems, apparatuses and methods may provide for technology that identifies a first namespace descriptor, a device memory descriptor, and a first request to execute a program on a logical volume that spans a plurality of physical drives, selects a first target drive from the plurality of physical drives based on the first namespace descriptor, and configures the first target drive to execute the program on first input data associated with the first namespace descriptor and write a first output of the program to a first memory region in an internal memory of the first target drive. In one example, the technology maps the device memory descriptor to the first memory region.

Abstract: Some embodiments provide a network forwarding integrated circuit (IC) that includes at least one packet processing pipeline. The packet processing pipeline includes multiple match-action stages, at least one of which includes a stateful processing unit that operates at a line rate of the network forwarding IC. The stateful processing unit is configured to receive data stored in a memory location associated with a stateful table of the match-action stage. The data includes a set of values. The stateful processing unit is further configured to identify one of a maximum value and a minimum value from the set of values, and to output the identified value for use by a next match-action stage.

Abstract: A method for classifying media content is disclosed. The method includes identifying, by a processing device, a plurality of search results corresponding to a search query, the plurality of search results corresponding to a plurality of media items; identifying, by the processing device, at least one first media item and a second media item of the plurality of media items, the first media item being associated with a first content label, the second media item being associated with a second content label; determining, based at least in part on a first user interaction with the first media item, whether the search query represents a request for media content associated with the first content label; and in response to determining that the search query represents the request for media content associated with the first content label, associating, by the processing device, the second media item with the first content label.

Abstract: Isolated antibodies that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT. In some embodiments, the antibodies are afucosylated.